August 2023, Vol 13, No 8
Where do we really stand when it comes to artificial intelligence (AI)? What is the value? Who is using it? What are the risks and drawbacks? This technology has been discussed as a solution to complicated medical management as long ago as the 1970s, in the early days of developing clinical decision support systems. Read More ›
Cancer clinical trials offer patients an opportunity to be treated with the most cutting-edge and promising therapies available, but the majority of patients who are offered these trials still are not signing up for them. This might frustrate those in the know, but many patients simply do not understand what these trials entail. However, navigators can play an important role in educating patients on clinical trials and making sure they do not miss out on these potentially lifesaving opportunities. Read More ›
A new study has found that partners of colorectal cancer survivors experienced long-term financial toxicity that was associated with worse health-related quality of life (HRQoL) due to systems- and individual-level behavioral factors. Read More ›
In the first phase, researchers conducted structured interviews with actual patients, testing their reactions to current and future AI technologies. In the second phase of the study, researchers polled 2472 participants across diverse ethnic, racial, and socioeconomic groups using a blinded, randomized survey that tested eight variables. Read More ›
A new study by investigators from Mass General Brigham, Boston, has found that artificial intelligence language models like ChatGPT can accurately identify appropriate imaging services for 2 important clinical presentations: breast cancer screening and breast pain. Read More ›
In the evolving landscape of today’s healthcare industry, more and more demands are being placed on practice managers and their staff. The proper training of these professionals is critical to operating a profitable, efficient, and compliant business so that providers can focus on the high-quality care that patients deserve. Read More ›
Generic medicines are the backbone of the US prescription drug market, supplying more than 9 out of every 10 prescriptions. And the production of generic medicines overall has been remarkably stable—even during challenges such as the COVID-19 pandemic. Read More ›
Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial. The results were presented during the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›
The following clinical trials represent a selection of key studies currently recruiting patients with gynecologic cancers for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to one of these trials. Read More ›